The PARP inhibitor, ABT-888 potentiates temozolomide: Correlation with Drug Levels and Reduction in PARP activity in Vivo

Anticancer Research

Volumn 28, Issue 5 A, 2008, Pages 2625-2635

  Palma, Joann P ^a   Rodriguez, Luis E ^a   Bontcheva Diaz, Velitchka D ^a   Bouska, Jennifer J ^a   Bukofzer, Gail ^a   Colon Lopez, Milagros ^a   Guan, Ran ^a   Jarvis, Kenneth ^a   Johnson, Eric F ^a   Klinghofer, Vered ^a   Liu, Xuesong ^a   Olson, Amanda ^a   Saltarelli, Mary J ^a   Shi, Yan ^a   Stavropoulos, Jason A ^a   Zhu, Gui Dong ^a   Penning, Thomas D ^a   Luo, Yan ^a   Giranda, Vincent L ^a   Rosenberg, Saul H ^a   Frost, David J ^a   Donawho, Cherrie K ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

ADP ribose; Biomarker; PARP; Preclinical efficacy; Temozolomide

Indexed keywords

ABT 888; ADENOSINE DIPHOSPHATE RIBOSE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; POLYMER; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VIVO STUDY; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CELL LINE, TUMOR; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; MELANOMA, EXPERIMENTAL; MICE; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES;

EID: 55749116351     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Virág L and Szabó C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375-429, 2002.
2. Jagtap P and Szabo C: Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Disc 4: 421-440, 2005.
3. Ju BG, Solum D, Song EJ, Lee KJ, Rose DW, Glass CK and Rosenfeld MG: Activating the PARP-1 sensor component of the groucho/TLE1 corepressor complex mediates a CaM kinase II delta-dependent neurogenic gene activation pathway. Cell 119: 815-829, 2004.
4. +- dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 119: 803-814, 2004.
5. Zardo G and Caiafa P: The unmethylated state of CpG islands in mouse fibroblasts depends on the poly(ADP-ribosyl)ation process. J Biol Chem 273: 16517-16520, 1998.
6. Zardo G, Reale A, Passananti C, Pradhan S, Buontempo S, De Matteis G, Adams RL and Caiafa P: Inhibition of poly(ADP-ribosyl)ation induces DNA hypermethylation: a possible molecular mechanism. FASEB J 16: 1319-1321, 2002.
7. Reale A, Matteis GD, Galleazzi G, Zampieri M and Caiafa P: Modulation of DNMT1 activity by ADP-ribose polymers. Oncogene 24: 13-19, 2005.
8. Rajesh M, Mukhopadhyay P, Batkai S, Godlewski G, Hasko G, Liaudet L and Pacher P: Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem Biophys Res Commun 350: 352-357, 2006.
9. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, Walztinger C, Chambon P and de Murcia G: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 94: 7303-7307, 1997.
10. Bernstein C, Bernstein H, Payne CM, Garewal, H: DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutation Res 511: 145-178, 2002.
11. Bryant H, Schultz N, Thomas H, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 434: 913-917, 2005.
12. Farmer H, McCabe N, Lord Christopher J, Tutt A, Johnson DA, Richardson TB, Santarosa M, Dillon-Krystyna J, Hickson I, Knights C, Martin N, Jackson-Stephen P, Smith Graeme CM and Ash worth A: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921, 2005.
13. Amé JC, Rolli V, Schreiber V, Niedergang, C, Apiou F, Decker P, Muller, S, Höger T, Ménissier de Murcia J and de Murcia G: PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 274: 17860-17868, 1999.
14. Johansson, M: A human poly(ADP-ribose) polymerase gene family (ADPKTL): cDNA cloning of two novel poly(ADP-ribose) polymerase homologues. Genomics 57: 442-445, 1999.
15. Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, Fraulob V, Menissier-de Murcia J and de Murcia G: Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277: 23028-23036, 2002.
16. Hayaishi O and Ueda K: Poly(ADP-ribose) and ADP-ribosylation of proteins. Ann Rev Biochem 46: 95-116, 1977.
17. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S and Taniguchi T: Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 37: 223-227, 1991.
18. Shiobara M, Miyazaki M, Ito H, Togawa A, Nakajima N, Nomura F, Morinaga N and Noda M: Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 16: 338-344, 2001.
19. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan WH, Ator M, Bihovsky R, Hudkins R, Chatterjee S, Klein-Szanto A, Dionne C and Ruggeri B: Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2: 371-382, 2003.
20. Tentori L, Leonetti C, Scarsella M, D Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J and Graziani G: Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9: 5370-5379, 2003.
21. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan KS, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ and Curtin NJ: Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96: 56-67, 2004.
22. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan KS, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z and Newell DR: Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 10: 881-889, 2004.
23. Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, Li H, Salzman AL, Dolan ME, Modrich P, Bigner DD and Friedman HS: Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 4: 1364-1368, 2005.
24. Tentori L and Graziani G: Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52: 25-33, 2005.
25. Donawho CK, Luo Y, Penning TD, Bauch, JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, Deweese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL and Frost DJ: ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13: 2728-2737, 2007.
26. Luo Y, Donawho C, Liu X, Shi Y, Guan R, Palma J, Zhu G, Johnson E, Rodriguez L, Bontcheva-Diaz V, Ghoreishi-Haack N, Jarvis J, Meulbroek J, Ferguson D, Cox B, Han E, McGonigal T, Klinghofer V, Olson A, Bouska J, Penning T, Rosenberg S, Frost D and Giranda V: ABT-888, a potent PARP inhibitor, enhances the antitumor activities by a variety of chemotherapeutic agents in vivo. In: American Association for Cancer Research Annual Meeting. Los Angeles, CA, USA, 2007.
27. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith Graeme CM and Ashworth A: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly ADP-ribose polymerase inhibition. Cancer Res 66: 8109-8115, 2006.
28. Ratnam K and Low J: Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 13: 1383-1388, 2007.
29. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJ, Brampton M and Stevens MF: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910-913, 1995.
30. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16: 3851-3857, 1998.
31. 6-alkylguanine-DNA- alkyltransferase. Clin Cancer Res 7: 2309-2317, 2001.
32. Kinders RJ, Palma J, Liu X, Colon-Lopez M, Luo Y, Rodriguez LE, Shi Y, Guan R, Hollingshead M, Joseph T, Giranda VL: Development of a quantitative enzyme immunoassay for measurement of PAR as a pharmacodynamic biomarker of PARP activity. In: The First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment. Chicago, IL, 2006.
33. Zhu GD, Gong J, Gandhi V, Penning TD and Giranda VL: 1H-Benzimidazole-4- carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors. United States patent application 2006/0229289. 2006.
34. Baud M: Data analysis, mathematical modeling. In: Methods of Immunological Analysis. Masseyeff R (ed.). New York, VCH Publishers, Inc., pp. 656-671, 1993.
35. Vera K, Djafari L, Faivre S, Guillamo JS, Djazouli K, Osorio M, Parker F, Cioloca C, Abdulkarim B, Armand JP and Raymond E: Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol 15: 161-171, 2004.
36. Bakondi E, Bai P, Szabo EE, Hunyadi J, Gergely P, Szabo C and Virag L: Detection of poly(ADP-ribose) polymerase activation in oxidatively stressed cells and tissues using biotinylated NAD substrate. J Histochem Cytochem 50: 91-98, 2002.
37. Palma JP, Rodriguez LE, Godzicki L, Jarvis K, Bontcheva-Diaz V, Colon-Lopez M, Saltarelli M, Liu X, Shi Y, Guan R, Luo Y, Olson A, Bouska J, Zhu G, Penning T, Joseph I, Wernet W, Grandel R, Giranda VL, Lesniewski R, Rosenberg S, Frost DJ and Donawho CK: Reduction in poly(ADP-ribose) polymer as a biological marker to demonstrate PARP inhibition by A-620223 and ABT-888 in vitro/in vivo. In: Keystone Symposia-Mouse Models at the Frontiers of Cancer Discovery. Whistler, British Columbia, CN, 2007.
38. 6- alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 11: 3402-3409, 2005.
39. Plummer R, Middleton M, Wilson R, Jones C, Evans J, Robson L, Steinfeldt H, Kaufman R, Reich S and Calvert AH: First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. In: Proceedings of the American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA, 2005.
40. Dalton WS: The tumor microenvironment: focus on myeloma. Cancer Treat Rev 29(Suppl 1): 11-19, 2003.
41. 6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl) 1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 304: 661-668, 2003.
42. Haince JF, Kozlov S, Dawson VL, Dawson TM, Hendzel MJ, Lavin MF and Poirier GG: ATM signaling network is modulated by a novel PAR-dependent pathway in the early response to DNA damaging agents. J Biol Chem 282: 16441-16453, 2007.
43. Malanga M and Althaus FR: The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem Cell Biol 83: 354-364, 2005.
44. Shah GM, Poirier D, Duchaine C, Brochu G, Desnoyers S, Lagueux J, Verreault A, Hoflack JC, Kirkland JB and Poirier GG: Methods for biochemical study of poly(ADP-ribose) metabolism in vitro and in vivo. Anal Biochem 227: 1-13, 1995.
45. Affar EB, Duriez PJ, Shah RG, Sallmann FR, Bourassa S, Kupper JH, Burkle A and Poirier GG: Immunodot blot method for the detection of poly(ADP-ribose) synthesized in vitro and in vivo. Anal Biochem 259: 280-283, 1998.
46. Massuda E, Stathis M, Alt J, Spicer E, Wu Y, Valentine H, Fuller M, Huang S, Lapidus R, Hoover R, Rojas C, Slusher B and Zhang J: Inhibition of PARP in B16 melanoma in mice treated with GPI 21016. In: Keystone Symposia-Molecular Targets for Cancer. Whistler, British Columbia, CN, 2007.
47. Yap T, Boss D, Fong P, Roelvink M, Tutt A, Carmichael J, O'Connor M, Kaye S, Schellens J and de Bono J: First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. In: American Association of Clinical Oncology Annual Meeting. Chicago, IL, USA, 2007.
48. Kummar S, Kinders R, Gutierrez M, Rubenstein L, Parchment R, Phillips L, Low J, Murgo A, Tomaszewski J, Doroshow J, NCI Phase 0 Working Group: Inhibition of poly(ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a Phase 0 trial. In: American Society of Clinical Oncologists Annual Meeting. Chicago, IL, USA, 2007.
49. Frank R and Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Disc 2: 566-580, 2003.
50. Lockett K, Hall L, Craig M, Xu J, Zheng S, Lilly L, Berwick M, Chuang S, Clark E, Peter E, Cramer SD, Lohman K and Hu JJ: The ADPKT V762A. genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 64: 6344-6348, 2004.
51. Wang XG, Wang ZQ, Tong WM and Shen Y: PARP1 Val762Ala polymorphism reduces enzymatic activity. Biochem Biophys Res Commun 354: 122-126, 2007.
52. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298, 2007.